Printed as of 4/25/2024



Disclosures

Personal Commercial (16)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbvie	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Actavis	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Amarin	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Amgen	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Caladrius	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Casana	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
CSL Behring	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Cytokinetics	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
Eli Liily	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Imara	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Moderan	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Reata	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Relypsa	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Salamandra	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2018	Testosterone	Plaintiff † Actavis	Case settled	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/22/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 3/22/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/22/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.